J Korean Med Assoc.  2010 Aug;53(8):695-704. 10.5124/jkma.2010.53.8.695.

Clinical Manifestations and Diagnosis of Gout

• Song JS

• KMID: 2188346
• DOI: http://doi.org/10.5124/jkma.2010.53.8.695

Abstract

Gout is a medical condition usually characterized by recurrent attacks of acute inflammatory arthritis involving, most commonly, the big toe, ankle, or other joints of the foot resulting from responses to the deposition of urate crystals from extracellular fluids supersaturated with urate. Middle aged men who are obese and drink alcohol regularly are the most susceptible. It is considered a chronic and progressive disease. Chronic gout can also lead to deposits of hard lumps of uric acid in the tissues, particularly in and around the joints, and may cause joint destruction, decreased kidney function, and kidney stones. It is associated with metabolic syndrome including dyslipidemia, hypertension, hyperglycemia, and obesity. Gout is suspected when a patient reports a history of attacks of painful arthritis, particularly at the base of the toes. A confirmative diagnosis of gout requires demonstration of monosodium urate crystals in the synovial fluid, tophi, or tissues.

Keyword

Gout; Uric acid; Acute arthritis; Renal insufficiency; Metabolic syndrome

MeSH Terms

Animals
Ankle
Arthritis
Dyslipidemias
Extracellular Fluid
Foot
Gout
Humans
Hyperglycemia
Hypertension
Joints
Kidney
Kidney Calculi
Male
Middle Aged
Obesity
Renal Insufficiency
Synovial Fluid
Toes
Uric Acid
Uric Acid

Figure

• 

  Figure 1 Activation of phagocyte by membrane-active crystals.

• 

  Figure 2 Factors affecting urate balance.

• 

  Figure 3 Acute gout attack presenting in the 1st metatarsophalangeal joint. Redness, swelling and severe tenderness on the affected joint are distinctive features.

• 

  Figure 4 Tohpi over the foot showing lumps of urate (arrows).

• 

  Figure 5 Monososodium urate crystals from tophus. Polarizing microscpoy shows needle shaped strong negative birefringent monosodium urate crystals. (×100)

• 

  Figure 6 Foot/ankle views on duel energy CT illustrating large tophaceous deposits at the first metatarsophalangeal joints and along the right Achilles tendon (arrowheads).

Reference

1. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005. 143:499–516.

2. Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA. 1991. 266:3004–3007.

3. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987. 82:421–426.

4. Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weiss-mann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest. 1995. 96:994–1002.

5. Getting SJ, Flower RJ, Parente L, de Medicis R, Lussier A, Woliztky BA, et al. Molecular determinants of monosodium urate crystal-induced murine peritonitis: a role for endogenous mast cells and a distinct requirement for endothelial-derived selectins. J Pharmacol Exp Ther. 1997. 283:123–130.

6. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004. 350:1093–1103.

7. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004. 363:1277–1281.

8. Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis. 1970. 29:461–468.

9. Becker MA, Jolly M. Koopman WJ, Moreland LW, editors. Clinical gout and the pathogenesis of hyperuricemia. Arthritis and allied conditions. 2005. 15th ed. Philadelphia: Lippincott Williams & Wilkins;2303–2339.

10. Lally EV, Ho G Jr, Kaplan SR. The clinical spectrum of gouty arthritis in women. Arch Intern Med. 1986. 146:2221–2225.

11. Nakayama DA, Barthelemy C, Carrera G, Lightfoot RW Jr, Wortmann RL. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum. 1984. 27:468–471.

12. Brown J, Mallory GK. Renal changes in gout. N Engl J Med. 1950. 243:325–329.

13. Talbott JH, Terplan KL. The kidney in gout. Medicine (Baltimore). 1960. 39:405–467.

14. Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, Chung SH, Kim CG, Choe JY, Lee SW, Chung WT, Song GG. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci. 2005. 20:1029–1033.

15. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998. 57:509–510.

16. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol. 1998. 8:250–261.

17. Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol. 1995. 142:288–294.

18. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health Professionals Follow-up Study. Arch Intern Med. 2005. 165:742–748.

19. Dieppe P, Swan A. Identification of crystals in synovial fluid. Ann Rheum Dis. 1999. 58:261–263.

20. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yü TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977. 20:895–900.

21. Choi HK, Al-Arfaj AM, Eftekhari A, Munk PL, Shojania K, Reid G, Nicolaou S. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis. 2009. 68:1609–1612.